As such, subjects with obesity and non-alcoholic fatty liver disease (NAFLD) have increased systemic FGF21 levels and hepatic mRNA expression, suggesting an “FGF21 resistant” [18] status, although this remains contentious [19]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.